Showing 1921-1930 of 3564 results for "".
- Novan Therapeutics Presents Data for Potential Topical Agent that Reduces Sebum in Acne Patientshttps://practicaldermatology.com/news/20130228-novan_therapeutics_presents_data_for_potential_topical_agent_that_reduces_sebum_in_acne_patients/2459602/Recent in vitro and animal testing data from Novan Therapeutics indicate that the company's drug candidate, SB204, could lead to a topical treatment for acne that reduces oil production in the skin. Dr. Diane Thiboutot, Professor of Dermatology at Penn State Hershey College of Medicine, notes that,
- Layoffs at Medicis top 300, with 117 staffers chosen to stayhttps://practicaldermatology.com/news/20130104-layoffs_at_medicis_top_300_with_117_staffers_chosen_to_stay/2459648/The layoff toll at Medicis Pharmaceutical has topped 300, the Phoenix Business Journal reports. Valeant Pharmaceuticals ($VRX), which wrapped up its buyout of the Arizona-based skin drug company last week, has cut 319 staffers--and kept 117--as it integrates Medicis into its own dermatology operatio
- Goldfaden MD to Donate to American Heart Association in 2013https://practicaldermatology.com/news/20121218-goldfaden_md_to_donate_to_american_heart_association_in_2013/2459656/Goldfaden MD plans to launch its Hands To Heart Anti-Aging Plus Brightening Hand Treatment in February 2013. In addition, ten percent of all proceeds from these purchases in February will be donated to the American Heart Association. The fast-
- Tofacitinib Citrate Approved for Rheumatoid Arthritishttps://practicaldermatology.com/news/20121203-tofacitinib_citrate_approved_for_rheumatoid_arthritis/2459668/Pfizer Inc. received US FDA approval for XELJANZ (tofacitinib citrate) 5mg twice daily for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. XELJANZ
- Merz, Inc. Acquires ONMEL Oral Treatment for Toenail Fungal Infectionshttps://practicaldermatology.com/news/20121128-merz_inc_acquires_onmel_oral_treatment_for_toenail_fungal_infections/2459671/Merz, Inc. completed the acquisition of ONMEL (itraconazole), an azole antifungal indicated for the oral treatment of onychomycosis of the toenail caused by Trichophyton rubrumor T. Mentagrophytes in non-immunocompromised patients. According to the compa
- LEO Pharma's Taclonex Topical Suspension Approved for Body Plaqueshttps://practicaldermatology.com/news/20121029-leo_pharma_receives_fda_approval_for_taclonex_topical_suspension/2459689/LEO Pharma Inc. announced the US Food and Drug Administration (FDA) approval of Taclonex (calcipotriene and betamethasone dipropionate) Topical Suspension, 0.005%/0.064% for the treatment of body plaque psoriasis. Taclonex® Topical Suspension is
- Health-Conscious Women 60% More Likely to Prefer Expensive Brand-Name Drugshttps://practicaldermatology.com/news/20121025-health-conscious_women_60_more_likely_to_prefer_expensive_brand-name_drugs/2459691/The consumer market research firm Scarborough analyzed "Health-Conscious Women," defined by Scarborough as American adult women who agree that they go to the doctor regularly for checkups, generally feel they eat right, and follow a regular exercise routine. Health-Conscious Women make up 16 percent
- Nuvo and Galderma Win FDA Approval for Topical Peelhttps://practicaldermatology.com/news/20121022-nuvo_and_galderma_win_fda_approval_for_topical_peel/2459699/Nuvo Research announced that the FDA has approved its Pliaglis product, a topical anesthetic cream designed to minimize pain during aesthetic dermatological procedures such as dermal filler injection, pulsed dye laser therapy, facial laser resurfacing, and laser-assisted tattoo removal. The approval
- Revance Regains Rights to Its Botulinum Toxinshttps://practicaldermatology.com/news/20121009-revance_regains_rights_to_its_botulinum_toxins/2459713/Revance Therapeutics, Inc. announced a settlement and termination agreement for its contractual relationships with Medicis Pharmaceutical Corporation concerning RT001 Botulinum Toxin Type A Topical Gel and RT002 Injectable Botulinum Toxin Type A.
- Bovie Medical Promotes Double Warranty, Free Goodshttps://practicaldermatology.com/news/20121002-bovie_medical_promotes_double_warranty_free_goods/2459723/Bovie Medical Corporation started its Fall Festival of Fun promotion now through December 31, 2012. During the promotion, customers receive an increased value of a double warranty and free goods when purchasing the Aaron® 1250, Aaron® 2250, or Aaron® 3250. To find out more information contact a loca